Nationwide Children's gene therapy spinoff inks option to be acquired by Sarepta

Sarepta Therapeutics Inc. has invested up to $105 million in the latest gene therapy spinoff from Nationwide Children's Hospital – Myonexus Therapeutics – and signed an option to acquire the company for an undisclosed but higher amount if clinical trial results are promising.